clinical trial tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo- controlled, phase 3 New Dual Incretin Agonist for

The influence of the gut microbiome on obesity, metabolic syndrome and gastrointestinal disease

When considered against active comparators, semaglutide also increased the likelihood of participants losing 5% fasting body weight, with ORs ranging from 1.29 (95% CI 0.70, 2.13 [T2DM]) to 2.17 (95% CI 1.44, 3.27 [NGT]) with liraglutide 3.0 mg and from 6.09 (95% CI 2.86, 11.95 [total population]) to 7.75 (95% CI 5.29, 11.37 [non-T2DM]) with orlistat 120 mg three times daily (TID)

One diabetes research pioneer, whose work paved the way for Ozempic, recently predicted GLP-1 drugs eventually may help treat dependence-related behaviors and even Alzheimers and Parkinsons diseases

Its killing people and disabling them in daily life